202 related articles for article (PubMed ID: 34001867)
21. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
[TBL] [Abstract][Full Text] [Related]
22. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
[TBL] [Abstract][Full Text] [Related]
23. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Oberic L; Peyrade F; Puyade M; Bonnet C; Dartigues-Cuillères P; Fabiani B; Ruminy P; Maisonneuve H; Abraham J; Thieblemont C; Feugier P; Salles G; Bijou F; Pica GM; Damaj G; Haioun C; Casasnovas RO; Farhat H; Le Calloch R; Waultier-Rascalou A; Malak S; Paget J; Gat E; Tilly H; Jardin F
J Clin Oncol; 2021 Apr; 39(11):1203-1213. PubMed ID: 33444079
[TBL] [Abstract][Full Text] [Related]
25. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
26. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
29. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
30. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Cortelazzo S; Rossi A; Viero P; Bellavita P; Marchioli R; Marfisi RM; Rambaldi A; Barbui T
Br J Haematol; 1997 Nov; 99(2):379-85. PubMed ID: 9375759
[TBL] [Abstract][Full Text] [Related]
31. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
32. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Zinzani PL; Pellegrini C; Argnani L; Broccoli A
Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
[No Abstract] [Full Text] [Related]
33. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
35. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma.
Hill H; Arnall J; Janes A; Hatley C; Swift K; Hargett C; Howell T; Griffin S; Larck C; Park S
J Oncol Pharm Pract; 2019 Dec; 25(8):2041-2044. PubMed ID: 30616469
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
[No Abstract] [Full Text] [Related]
37. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
[TBL] [Abstract][Full Text] [Related]
39. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F; Ghosh N; Lossos IS; Palomba ML; Mehta A; Casasnovas O; Stevens D; Katakam S; Knapp A; Nielsen T; McCord R; Salles G
Blood Cancer J; 2021 Aug; 11(8):147. PubMed ID: 34417444
[TBL] [Abstract][Full Text] [Related]
40. Salvage therapy with PROMACE in relapsed non-Hodgkin malignant lymphoma.
Nielsen H
Eur J Haematol; 1991 Feb; 46(2):123-4. PubMed ID: 1995324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
